Enzo Biochem was founded in 1976 and is headquartered in New York, US

Enzo Biochem has an office in New York

New York, US (HQ)

527 Madison Ave

Enzo Biochem's revenue was reported to be $27.1 m in Q3, 2017

USD

## Revenue (Q3, 2017) | 27.1 m |

## Net income (Q3, 2017) | (2.6 m) |

## EBIT (Q3, 2017) | (227 k) |

## Market capitalization (18-Aug-2017) | 499.8 m |

## Cash (30-Apr-2017) | 62.6 m |

Enzo Biochem's current market capitalization is $499.8 m.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 93.7 m | 95.9 m | 97.6 m | 102.8 m |

## Revenue growth, % | 2% | 2% | 5% | |

## R&D expense | 3.5 m | |||

## Operating expense total | 112.7 m | 106.1 m | 98.8 m | 55.8 m |

## EBIT | (19 m) | (10.2 m) | (1.2 m) | 47 m |

## EBIT margin, % | (20%) | (11%) | (1%) | 46% |

## Interest expense | 54 k | 208 k | 245 k | 136 k |

## Pre tax profit | (18.9 m) | (9.9 m) | (2.3 m) | 46.5 m |

## Income tax expense | (712 k) | 72 k | (7 k) | 1.2 m |

## Net Income | (18.2 m) | (10 m) | (2.3 m) | 45.3 m |

USD | Q1, 2014^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2017^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 24.8 m | 23.1 m | 24 m | 25.2 m | 24.6 m | 26.4 m | 26.3 m | 26.3 m | 27.1 m |

## R&D expense | 791 k | 834 k | 809 k | 867 k | 861 k | 882 k | 822 k | 483 k | 766 k |

## General and administrative expense | 11.2 m | 10.5 m | |||||||

## Operating expense total | 791 k | 834 k | 809 k | 867 k | 861 k | 882 k | 822 k | 11.6 m | 11.3 m |

## EBIT | (3.1 m) | (3.9 m) | (2.8 m) | 4.6 m | 7.5 m | (2.5 m) | (1.3 m) | (1 m) | (227 k) |

## EBIT margin, % | (12%) | (17%) | (12%) | 18% | 30% | (10%) | (5%) | (4%) | (1%) |

## Interest expense | (69 k) | (49 k) | (58 k) | (40 k) | (42 k) | (40 k) | 46 k | 79 k | 115 k |

## Pre tax profit | (3.6 m) | (4.2 m) | (3 m) | 4.5 m | 7 m | (2.1 m) | (1.5 m) | (1 m) | (39 k) |

## Income tax expense | (123 k) | (87 k) | (207 k) | (2 k) | (20 k) | (53 k) | (32 k) | ||

## Net Income | (3.7 m) | (7.8 m) | (10.7 m) | 4.4 m | 11.3 m | 9.2 m | (1.5 m) | (2.5 m) | (2.6 m) |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 9 m | 17.5 m | 18.1 m | 67.8 m |

## Accounts Receivable | 12.3 m | 12.5 m | 6.7 m | 6.7 m |

## Inventories | 8.8 m | 8.7 m | 7.4 m | 7 m |

## Current Assets | 32.6 m | 40.7 m | 46.5 m | 91.4 m |

## PP&E | 8.6 m | 7.7 m | 7.9 m | 8.2 m |

## Goodwill | 7.5 m | 7.5 m | 7.5 m | 7.5 m |

## Total Assets | 59 m | 64.4 m | 68.4 m | 111.8 m |

## Current Liabilities | 23.9 m | 25 m | 24 m | 20.6 m |

## Total Liabilities | 22.3 m | |||

## Additional Paid-in Capital | 304.3 m | 317.2 m | 325 m | 326.3 m |

## Retained Earnings | (272.4 m) | (282.4 m) | (284.7 m) | (239.4 m) |

## Total Equity | 34.1 m | 37 m | 42.6 m | 89.6 m |

## Financial Leverage | 1.7 x | 1.7 x | 1.6 x | 1.2 x |

USD | Q1, 2014^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2017^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 16.6 m | 15.3 m | 14.4 m | 30.6 m | 37 m | 32.4 m | 67.2 m | 62.4 m | 62.6 m |

## Accounts Receivable | 6.7 m | 6.7 m | |||||||

## Inventories | 8.5 m | 8.3 m | 8 m | 7.6 m | 7.4 m | 7 m | 7.2 m | 7.1 m | 7.2 m |

## Current Assets | 39.7 m | 37 m | 36.1 m | 52.8 m | 59.2 m | 55.2 m | 90.4 m | 86.9 m | 87.5 m |

## PP&E | 7.5 m | 7.6 m | 8 m | 8.1 m | 8.7 m | 8.6 m | 8.3 m | 8.2 m | 8.1 m |

## Goodwill | 7.5 m | 7.5 m | 7.5 m | 7.5 m | 7.5 m | 7.5 m | 7.5 m | 7.5 m | 7.5 m |

## Total Assets | 62.6 m | 59.5 m | 58.5 m | 74.4 m | 80.9 m | 76.5 m | 110.5 m | 106.4 m | 106.6 m |

## Current Liabilities | 24.5 m | 22.7 m | 22.5 m | 25.8 m | 24.5 m | 21.7 m | 20.8 m | 17.6 m | 17 m |

## Additional Paid-in Capital | 319.9 m | 322.7 m | 324.9 m | 325.1 m | 325.3 m | 326.1 m | 326.4 m | 326.8 m | 327.8 m |

## Retained Earnings | (286.1 m) | (290.2 m) | (293.1 m) | (280.2 m) | (273.4 m) | (275.5 m) | (240.9 m) | (241.9 m) | (242 m) |

## Total Equity | 47.2 m | 54.4 m | 53 m | 88.5 m | 87.7 m | 88.6 m | |||

## Financial Leverage | 1.6 x | 1.5 x | 1.4 x | 1.2 x | 1.2 x | 1.2 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (18.2 m) | (10 m) | (2.3 m) | 45.3 m |

## Accounts Receivable | (2.6 m) | (3.2 m) | (2 m) | (4.8 m) |

## Inventories | 60 k | 159 k | 1.2 m | 466 k |

## Cash From Operating Activities | (10 m) | (1.7 m) | (3.7 m) | 53.1 m |

## Capital Expenditures | (988 k) | (838 k) | (1.8 m) | (1.5 m) |

## Cash From Investing Activities | (971 k) | (833 k) | (1.8 m) | (1.5 m) |

## Cash From Financing Activities | 4.8 m | 10.9 m | 6.2 m | (1.9 m) |

## Free Cash Flow | (11 m) | (2.5 m) | (5.5 m) | 51.6 m |

USD | Q1, 2014^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2017^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (3.7 m) | (7.8 m) | (10.7 m) | 4.4 m | 11.3 m | 9.2 m | (1.5 m) | (2.5 m) | (2.6 m) |

## Accounts Receivable | (482 k) | (524 k) | (940 k) | (1.4 m) | (2 m) | (3 m) | (150 k) | (2.2 m) | (3.2 m) |

## Inventories | 107 k | 306 k | 597 k | (210 k) | (20 k) | 447 k | (298 k) | (238 k) | (213 k) |

## Cash From Operating Activities | (2.8 m) | (6.5 m) | (8.2 m) | 13.2 m | 20.1 m | 17 m | (333 k) | (2.8 m) | (1.9 m) |

## Capital Expenditures | (264 k) | (653 k) | (1.2 m) | (505 k) | (943 k) | (1.4 m) | (514 k) | (689 k) | (1.4 m) |

## Cash From Investing Activities | (259 k) | (653 k) | (1.2 m) | (490 k) | (941 k) | (1.4 m) | (514 k) | (687 k) | (1.4 m) |

## Cash From Financing Activities | 2.2 m | 5.1 m | 6.4 m | (125 k) | (192 k) | (1.4 m) | 303 k | (1.8 m) | (1.8 m) |

## Free Cash Flow | (3 m) | (7.1 m) | (9.3 m) | 12.6 m | 19.1 m | 15.6 m | (847 k) | (3.5 m) | (3.3 m) |

Y, 2017 | |
---|---|

## Financial Leverage | 1.2 x |